Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Karafin MS, DeSimone RA, Dvorak J, Metcalf RA, Pagano MB, Park YA, et al. Antibody Titers in Transfusion Medicine: A Critical Reevaluation of Testing Accuracy, Reliability, and Clinical Use. Arch Pathol Lab Med. 2023;147(12):1351-1359.

Forlenza CJ, Chadburn A, Giulino-Roth L. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults. J Natl Compr Canc Netw. 2023;21(3):323-330.

Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo M-, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023;75(10):1687-1702.

Barrera C, Corredor G, Viswanathan VS, Ding R, Toro P, Fu P, et al. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. NPJ Precis Oncol. 2023;7(1):52.

Limberg J, Lee-Saxton YJ, Egan CE, AlAnazi AA, Easthausen I, Stefanova D, et al. Perineural Invasion in Papillary Thyroid Cancer: A Rare Indicator of Aggressive Disease. Ann Surg Oncol. 2023;30(6):3570-3577.

Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, et al. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. bioRxiv. 2023.

Elhadad S, Redmond D, Tan A, Huang J, Rodriguez BL, Racine-Brzostek SE, et al. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. Thromb Res. 2023;225:47-56.

Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med. 2023;21(1):75.

Magro CM, Kalomeris T, Roberts A. Primary cutaneous blastic marginal zone lymphoma: A comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal. Ann Diagn Pathol. 2023;63:152101.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, et al. Novel genetically engineered mouse models for clear cell renal cell carcinoma. Sci Rep. 2023;13(1):8246.